Latest From Celularity Inc.
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.
Investments of over $100 million are now close to becoming the predominant class of venture capital deployed in the life sciences. What is behind this shift in venture investing and how might it impact companies' strategy to attract the big bucks.
Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.
- Gene Therapy, Cell Therapy
- Medical Devices
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Company Type
- Parent & Subsidiaries
- Celularity Inc.
- Senior Management
Robert Hariri, MD, PhD, Chmn. & CEO
Jerome Zeldis, MD, PhD, CMO
Xiaokui Zhang, PhD, CSO
Carlos Ramirez, Chief Marketing Officer
- Contact Info
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.